Ann: Annual Report to shareholders, page-70

It may well be rose coloured glasses @skorpion but the company must push through the barriers, of which there are many. A good example is RAP. Their trial did indeed fail but they refused to walk away from the technology. They are now valued at $160M approx. (after falling from >$300M to around $30M).

MEB's trial on the other hand did not fail. Some are rightly questioning the commercial potential given the latest results, but it did not fail. It is still better than widely reported accuracy of medical practitioners. Incidentally, earlier trials (prior to the current CEO) were achieving 78%-88%.